Additive Anti-inflammatory Action for Aortopathy & Arteriopathy

Launched by NANJING MEDICAL UNIVERSITY · May 19, 2020

Keywords

ClinConnect Summary

Aortopathy represent a major clinical challenge and are regarded as one of the leading causes of mortality among cardiovascular disorders. However, the pathological mechanisms underlying aortopathy are still far from being well understood, which makes treating this life-threatening challenging. It is increasingly clear that inflammation plays a key role in the development and progression of acute aortic syndrome (AAS) independent of cholesterol and other traditional risk factors, and characterizes both systemic and local condition.

Currently, surgery is considered the best treatment option...

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Aged 18 years or older.
• • Patients with diagnosis of AAS, including aortic dissection, penetrating aortic ulcer or intramural hematoma.
• • Symptoms started within 14 days from surgery.
• • Patients received medical therapy, open surgical, endovascular, or hybrid repair.
• • Any other major cardiac surgical procedure concomitant with surgery for AAS, such as coronary artery bypass grafting or carotid artery replacement;
• • The patient or guardian agrees to participate in this study. Exclusion criteria
• • Patients aged \< 18 years.
• • Onset of symptoms \> 14 days from surgery.
• • AAS secondary to traumatic or iatrogenic injury.
• • Patients who declined participation in registration and follow-up investigation.